Opioid detox for Miami — fentanyl-era protocols, buprenorphine done right.

RECO Island is a private, physician-led detox and residential rehab in Delray Beach — roughly 65 minutes up I-95 from Brickell, Coral Gables, or Coconut Grove. Opioid detox is COWS-guided, buprenorphine-forward, and calibrated for the fentanyl era, with 24/7 nursing, physician management, and direct in-house transition into residential treatment on the same campus. No waitlists, no third-party handoffs, and no discharge without a MAT plan, naloxone in hand, and family education completed.

From Brickell, Coral Gables, or Coconut Grove, the run up I-95 to RECO Island’s Delray Beach campus is roughly 50 miles — about 65 minutes without traffic, and longer through rush hour. That distance is not incidental to the clinical work. Miami clients who enter opioid detox at RECO Island typically stay on-site through the acute withdrawal window and transition directly into residential treatment on the same campus, putting real geographic space between themselves and the neighborhoods, dealers, and social circles where use took hold.

Opioid withdrawal in the fentanyl era

Fentanyl and its analogs have materially rewritten opioid withdrawal management. Compared to heroin or oxycodone, illicit fentanyl produces withdrawal that emerges faster, hits harder, and follows a less predictable arc — a function of high mu-receptor potency, short plasma half-life, and lipophilic accumulation in adipose tissue that can seed prolonged, atypical symptom profiles well beyond the classic five-to-seven day window.

Buprenorphine induction has historically been initiated at 12-24 hours of moderate withdrawal, when a Clinical Opiate Withdrawal Scale (COWS) score crosses roughly 11. In fentanyl-exposed patients, that same protocol carries a materially higher risk of precipitated withdrawal — buprenorphine’s partial agonism can displace residual fentanyl from receptors and produce a sudden, severe symptom cascade. RECO Island’s protocol accounts for this with extended pre-induction observation, low-dose micro-induction options, and physician-directed dosing rather than a fixed schedule.

Street opioid supply across South Florida — including Miami-Dade — has been effectively fentanyl-dominant for several years. Adulterants including xylazine (“tranq”), benzodiazepines, and novel synthetic opioids complicate assessment further and are factored into intake screening, monitoring frequency, and comfort-medication decisions.

COWS-guided buprenorphine induction

The COWS instrument scores eleven objective and subjective withdrawal domains — resting pulse, sweating, restlessness, pupil size, bone and joint aches, rhinorrhea and lacrimation, GI upset, tremor, yawning, anxiety, and gooseflesh skin — each on a defined scale. Nursing staff score COWS at set intervals through the acute window; scores drive comfort-medication dosing and the timing of buprenorphine induction rather than a clock.

Standard induction begins with 2-4 mg buprenorphine/naloxone once COWS crosses the moderate threshold, with additional 2-4 mg doses titrated over the first 24 hours to a clinically effective total — usually 8-16 mg daily, occasionally higher in heavy fentanyl exposure. For clients who cannot tolerate standard induction, low-dose (Bernese) protocols allow buprenorphine to be started while residual full-agonist exposure declines, avoiding the precipitated withdrawal window.

Comfort medications cover what buprenorphine alone doesn’t: clonidine for autonomic hyperarousal, loperamide for diarrhea, ondansetron for nausea, cyclobenzaprine or methocarbamol for muscle cramps, hydroxyzine or trazodone for insomnia and anxiety. Concurrent psychiatric comorbidity is the rule rather than the exception in opioid use disorder; PHQ-9 and GAD-7 screening at intake informs medication decisions, often involving sertraline, mirtazapine, or other non-controlled options during the stay.

Buprenorphine, methadone, or naltrexone — the MAT decision

Post-detox medication-assisted treatment for opioid use disorder has three evidence-based options, each with a distinct profile. Buprenorphine is a partial mu agonist with a ceiling effect on respiratory depression and can be continued through office-based prescribers. Methadone is a full mu agonist dispensed only through federally licensed opioid treatment programs, with the strongest evidence base for retention. Extended-release naltrexone (Vivitrol) is a mu antagonist given as a monthly intramuscular injection and requires a 7-10 day opioid-free window before the first dose to avoid precipitated withdrawal.

The MAT decision is made with the client during the detox stay, weighing prior response, pregnancy status, work and driving considerations, treatment access at discharge, and personal preference. Miami clients returning to Brickell, Aventura, or Pinecrest have local access to buprenorphine prescribers and Vivitrol clinics; methadone continuation requires enrollment in a Miami-Dade opioid treatment program before discharge, coordinated by RECO Island case management.

The evidence that MAT reduces all-cause and overdose-specific mortality compared to detox alone is not seriously contested. Discharge from opioid detox without a MAT plan is not consistent with current standard of care and is not how opioid detox at RECO Island is practiced.

Naloxone education and the safety net

Every opioid detox client at RECO Island — and, when consent permits, family members — receives naloxone education and a take-home prescription before discharge. Overdose risk is highest in the weeks immediately following detox: opioid tolerance drops rapidly during the abstinence window, while return-to-use risk in the first 30 days remains real regardless of MAT status. A single relapse at pre-detox doses can be fatal.

Naloxone (Narcan) is a short-acting mu antagonist that reverses opioid-induced respiratory depression when administered intranasally or intramuscularly. Family training covers recognition of overdose signs — unresponsiveness, cyanosis, agonal breathing — administration technique, recovery positioning, and the requirement to call 911. Naloxone’s duration (30-90 minutes) is often shorter than the offending opioid’s, particularly with fentanyl, so repeat dosing and monitored transport are expected.

The combination of MAT continuation, naloxone in the home, and family harm-reduction education constitutes the evidence-based standard for reducing the post-detox mortality window. It is embedded in the discharge protocol as clinical practice, not optional programming.

What to expect on your first day

Admission from Miami typically begins with a phone consultation and insurance verification, followed by a same-day or next-day intake window depending on medical acuity. Admissions coordinates transportation from Miami-Dade for clients who cannot safely drive themselves — a common scenario given active withdrawal, and one that should not delay treatment entry.

On arrival, clients complete a physician history and physical, psychiatric evaluation, ASAM Criteria assessment across the six dimensions (acute intoxication and withdrawal potential, biomedical, emotional-behavioral, readiness to change, relapse potential, and recovery environment), and baseline labs including CBC, CMP, hepatitis panel, and urine drug screen. Vitals and COWS trending begin immediately, and comfort medications start at the first indicated dose rather than waiting for a scheduled round.

Insurance and admissions from Miami

RECO Island works with major commercial insurers including Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans, with in-network status varying by product line. Verification of benefits — deductible, coinsurance, prior authorization requirements, and level-of-care approvals — is completed before arrival so families understand financial exposure up front rather than after discharge.

The 65-minute drive from Miami-Dade means clients and families should plan for a residential rather than commuting model. Family visitation, phased communication protocols, and structured family therapy sessions are built into the timeline once acute withdrawal has resolved and cognitive function has returned to baseline.

Serving residents of: Brickell, Coral Gables, Coconut Grove, Aventura, Pinecrest.